Biochemics sec
WebDec 14, 2012 · SEC Charges Massachusetts Company, CEO and Promoters With $9 Million Securities Fraud Recently, the Securities and Exchange Commission filed an enforcement action in federal court in Boston against BioChemics, Inc., a biopharmaceutical company based in Danvers, Massachusetts, its CEO and two individuals it paid to solicit investors. WebDeveloper of transdermal drug delivery technology designed to offer treatment for the skin.
Biochemics sec
Did you know?
WebAug 7, 2013 · BioChemics is a specialty pharmaceutical company focused on transdermal drug delivery systems, including medicated lotions. Masiz is BioChemics's president and chief executive officer. In May 2011 and September 2011, the SEC served document subpoenas on BioChemics requesting a broad range of documents regarding the … Web•the SEC served deposition subpoenas on Masiz and two other individuals in January 2012 (during the policy period); • the SEC served document subpoenas on Biochemics and Masiz in March 2012 (during the policy period); and • the SEC filed an enforcement action against Biochemics, Masiz, and two promoters retained by the company in December …
WebIn 2015, the SEC won a $17.2 million judgment against BioChemics stemming from an allegation that BioChemics misled 70 investors by exaggerating the positive test results … WebMar 4, 2024 · biochemistry, study of the chemical substances and processes that occur in plants, animals, and microorganisms and of the changes they undergo during …
WebDec 14, 2012 · BioChemics of Danvers faces fraud charges By Beth Healy Globe Staff,December 14, 2012, 2:17 p.m. Federal securities regulators on Friday filed civil fraud charges against BioChemics Inc. of... WebAug 29, 2024 · According to the complaint, when BioChemics finally did conduct one clinical trial, it misrepresented the results of that trial. The complaint further alleged that Masiz …
WebBiochemists work in industries like agriculture, medical research, biotechnology and nutritional research. Our students go on to positions in research and industry, as well as graduate study in biochemistry, …
WebAug 22, 2024 · According to the SEC complaint, BioChemics, Masiz and co-conspirators were accused of engaging in a fraudulent scheme to sell company securities to approximately 70 investors. The scheme, which ran from 2009 until the middle of 2012, netted at least $9 million. Investors caught up in the scheme resided in 19 different states. lithium battery lt14h504357wWebMar 25, 2015 · The judgment entered on March 25, 2015, supplements the March 18, 2015 judgment, and requires BioChemics to disgorge $15,105,325 in ill-gotten gains plus … improving plano texasWebbiochemistry: [noun] chemistry that deals with the chemical compounds and processes occurring in organisms. improving police-community relationsWebJan 14, 2014 · Biochemics, Inc. Overview. Biochemics, Inc. filed as a Foreign For-Profit Corporation in the State of Texas on Tuesday, January 14, 2014 and is approximately nine years old, as recorded in documents filed with Texas Secretary of State.A corporate filing is called a foreign filing when an existing corporate entity files in a state other than the state … improving platelet count naturallyWebJan 6, 2015 · Plaintiffs BioChemics, Inc., and John Masiz sued defendant Axis Reinsurance Company (“AXIS”) for defense costs arising out of a Securities and Exchange Commission (“SEC”) investigation and enforcement action under their directors and officers (“D & O”) liability insurance policy. improving police and community relationsWebMay 23, 2024 · Plaintiffs sought damages for what they claimed was AXIS's breach, under the relevant policy, of its duty to defend them in connection with an investigation conducted by the Securities and Exchange Commission against BioChemics and its officers. improving police accountabilityWebSep 6, 2024 · In Biochemics, Inc. v. AXIS Reinsurance Company, 2024 WL 2223125 (1st Cir. 2024), the SEC issued a subpoena to Biochemics on May 5, 2011, requesting that Biochemics produce certain documentation in connection with the SEC’s investigation into whether Biochemics and its President and CEO, John Masiz, had committed securities … improving planning